Physician profile
Divya Chode
NPI 1598040339
$2,301.70
in general payments reported to CMS, 2019-2025
14 companies · $343 in 2025
The $343 reported for 2025 was more than what 86% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $135 · 2021: $462 · 2022: $244 · 2023: $527 · 2024: $238 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $918.63 | 2019-2024 | Xarelto |
| Pfizer INC. | $315.60 | 2019-2025 | |
| Inari Medical, INC. | $232.30 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $153.89 | 2023 | Mitraclip |
| Novo Nordisk INC | $134.73 | 2020 | |
| Genzyme Corporation | $120.82 | 2025 | |
| Ardelyx, INC. | $119.61 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.22 | 2021-2025 | Xifaxan |
| Medtronic, INC. | $54.06 | 2022 | |
| Abiomed | $47.52 | 2025 | |
| Scpharmaceuticals INC. | $29.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.12 | 2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Allergan, INC. | $24.64 | 2019 | |
| Glaxosmithkline, LLC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Chode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.